MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising Safety Profile in Comparison to Traditional Ketamine In Preclinical Testing

MIRA Pharmaceuticals, Inc. today announced new compelling preclinical results for its investigational compound, Ketamir-2, a novel oral ketamine analog.